SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

Schedule of segment revenues and profit

Segment revenues and profits were as follows:

	Three Months Ended September 30,						Nine Months Ended September 30,
(in millions)	2019			2018			2019			2018
Revenues:
Bausch + Lomb/International	$	1,175		$	1,147		$	3,501		$	3,459
Salix	551			460			1,505			1,323
Ortho Dermatologics	147			176			407			457
Diversified Products	336			353			964			1,020
	$	2,209		$	2,136		$	6,377		$	6,259
Segment profits:
Bausch + Lomb/International	$	333		$	341		$	989		$	988
Salix	375			304			995			868
Ortho Dermatologics	58			88			156			190
Diversified Products	246			267			714			766
	1,012			1,000			2,854			2,812
Corporate	(158		)	(167		)	(435		)	(442		)
Amortization of intangible assets	(475		)	(658		)	(1,452		)	(2,142		)
Goodwill impairments	—			—			—			(2,213		)
Asset impairments	(33		)	(89		)	(49		)	(434		)
Restructuring and integration costs	(4		)	(3		)	(28		)	(16		)
Acquisition-related contingent consideration	(3		)	19			(2		)	23
Other income (expense), net	(10		)	15			(15		)	3
Operating income (loss)	329			117			873			(2,409		)
Interest income	2			3			9			9
Interest expense	(406		)	(420		)	(1,221		)	(1,271		)
Loss on extinguishment of debt	—			—			(40		)	(75		)
Foreign exchange and other	9			—			12			18
Loss before benefit from (provision for) income taxes	$	(66	)	$	(300	)	$	(367	)	$	(3,728	)

Schedule of revenues by segment and product category

Revenues by segment and product category were as follows:

	Three Months Ended September 30, 2019										Three Months Ended September 30, 2018
(in millions)	Bausch + Lomb/ International		Salix		Ortho Dermatologics		Diversified Products		Total		Bausch + Lomb/ International		Salix		Ortho Dermatologics		Diversified Products		Total
Pharmaceuticals	$	217	$	551	$	97	$	207	$	1,072	$	222	$	460	$	140	$	233	$	1,055
Devices	375		—		46		—		421		365		—		29		—		394
OTC	371		—		—		—		371		352		—		—		—		352
Branded and Other Generics	197		—		—		119		316		192		—		—		115		307
Other revenues	15		—		4		10		29		16		—		7		5		28
	$	1,175	$	551	$	147	$	336	$	2,209	$	1,147	$	460	$	176	$	353	$	2,136

	Nine Months Ended September 30, 2019										Nine Months Ended September 30, 2018
(in millions)	Bausch + Lomb/ International		Salix		Ortho Dermatologics		Diversified Products		Total		Bausch + Lomb/ International		Salix		Ortho Dermatologics		Diversified Products		Total
Pharmaceuticals	$	670	$	1,505	$	265	$	617	$	3,057	$	667	$	1,323	$	346	$	714	$	3,050
Devices	1,127		—		130		—		1,257		1,117		—		90		—		1,207
OTC	1,063		—		—		—		1,063		1,046		—		—		—		1,046
Branded and Other Generics	582		—		—		332		914		576		—		—		294		870
Other revenues	59		—		12		15		86		53		—		21		12		86
	$	3,501	$	1,505	$	407	$	964	$	6,377	$	3,459	$	1,323	$	457	$	1,020	$	6,259

Schedule of revenue attributed to a geographic region

Revenues are attributed to a geographic region based on the location of the customer and were as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
(in millions)	2019		2018		2019		2018
U.S. and Puerto Rico	$	1,369	$	1,329	$	3,851	$	3,766
China	86		91		276		273
Canada	85		78		252		231
Japan	67		59		181		165
Mexico	56		56		158		153
Egypt	55		45		157		134
France	45		46		156		159
Poland	49		49		156		164
Russia	47		38		124		106
Germany	33		38		119		130
United Kingdom	27		29		85		87
Italy	18		19		62		64
Spain	18		17		62		61
Other	254		242		738		766
	$	2,209	$	2,136	$	6,377	$	6,259

Schedule of customers that accounted for 10% or more of total revenue

Customers that accounted for 10% or more of total revenues were as follows:

	Nine Months Ended September 30,
	2019	2018
McKesson Corporation (including McKesson Specialty)	17%	18%
AmerisourceBergen Corporation	17%	18%
Cardinal Health, Inc.	14%	13%